欢迎您访问《中华养生保健》官方网站！

中华养生保健 ›› 2025, Vol. 43 ›› Issue (11): 173-176.

• 经验交流 • 上一篇    下一篇

免疫T淋巴细胞亚群指标与晚期结直肠癌患者化疗联合靶向治疗疗效及预后的关系研究

曹婷1, 肖铟2, 张程2, 郑广2, 王珏2, 黄世颖3, 何欣2,*   

  1. 1.齐齐哈尔医学院病理学院基础病理教研室,黑龙江 齐齐哈尔,161000;
    2.齐齐哈尔医学院附属第三医院肿瘤一科,黑龙江 齐齐哈尔,161000;
    3.齐齐哈尔医学院附属第三医院外科,黑龙江 齐齐哈尔,161000
  • 出版日期:2025-06-01 发布日期:2025-09-23
  • 通讯作者: *何欣,E-mail：hexinlhyd2024@163.com。
  • 作者简介:曹婷（1990—）,女,汉族,籍贯：黑龙江省齐齐哈尔市,硕士研究生,主治医师,研究方向：消化道肿瘤。
  • 基金资助:
    齐齐哈尔市科技计划联合引导项目（LSFGG-2024029）

Study on the Relationship between Immune Tlymphocyte Subsets and the Efficacy and Prognosis of Chemotherapy Combined Targeted Therapy in Patients with Advanced Colorectal Cancer

CAO Ting1, XIAO Yin2, ZHANG Cheng2, ZHENG Guang2, WANG Jue2, HUANG Shi-ying3, HE Xin2,*   

  1. 1. Department of Basic Pathology, School of Pathology, Qiqihar Medical University, Qiqihar Heilongjiang, 161000, China;
    2. Department of Oncology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar Heilongjiang, 161000, China;
    3. Department of Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar Heilongjiang, 161000, China
  • Online:2025-06-01 Published:2025-09-23

PDF (PC)

0

摘要： 目的 探究免疫T淋巴细胞亚群指标与晚期结直肠癌（CRC）患者化疗联合靶向治疗疗效及预后的关系。方法 选取2024年1月—2024年10月齐齐哈尔医学院附属第三医院的晚期CRC患者85例作为研究对象。所有患者均接受化疗联合靶向治疗,4个周期后对比两组疗效,根据患者疗效将其分为控制组（55例,完全缓解+部分缓解+疾病稳定）与无效组（30例,疾病进展）。对比两组免疫功能和肿瘤指标。结果 治疗前,两组的CD3+T细胞、CD4+T细胞、CD8+T细胞、CD4+/CD8+水平比较,差异无统计学意义（P>0.05）;治疗后,控制组的CD3+T细胞、CD4+T细胞、CD4+/CD8+水平高于无效组,控制组的CD8+T细胞水平低于无效组,差异有统计学意义（P<0.05）。治疗前,两组的肿瘤异常糖链糖蛋白（TAP）、糖类抗原125（CA125）、糖类抗原199（CA199）水平比较,差异无统计学意义（P>0.05）;治疗后,控制组的TAP、CA125、CA199水平低于无效组,差异有统计学意义（P<0.05）。治疗后,CD3+T细胞、CD4+T细胞、CD4+/CD8+水平与治疗疗效呈负相关,差异有统计学意义（P<0.05）,CD8+T细胞水平与治疗疗效呈正相关,差异有统计学意义（P<0.05）。结论 免疫T淋巴细胞亚群指标与晚期结直肠癌患者化疗联合靶向治疗疗效有潜在关联,对患者预后具有重要意义。

关键词: 晚期结直肠癌, 免疫T淋巴细胞亚群, 免疫功能, 肿瘤指标

Abstract: Objective To explore the relationship between immune T lymphocyte subsets and the efficacy and prognosis of patients with advanced colorectal (CRC) cancer treated with chemotherapy combined with targeted therapy. Methods A total of 85 patients with advanced CRC were selected from January 2024 to October 2024. All patients received chemotherapy combined with targeted therapy. After 4 cycles, the efficacy of the two groups was compared. According to the efficacy of the patients, they were divided into a control group (55 cases, complete response + partial response + stable disease) and an ineffective group (30 cases, disease progression). The immune function and tumor indexes were compared between the two groups. Results Before treatment, there was no significant difference in the levels of CD3+T cells, CD4+T cells, CD8+T cells and CD4+/CD8+ between the two groups (P>0.05). After treatment, the levels of CD3+T cells, CD4+T cells and CD4+/CD8+ in the control group were higher than ineffective group, and the levels of CD8+T cells in the control group were lower than those in the ineffective group, with statistical significance (P< 0.05). Before treatment, there was no significant difference in tumor abnormal protein (TAP), Carbohydrate antigen 125 (CA125) and Carbohydrate antigen 199 (CA199) levels between the two groups (P>0.05). After treatment, TAP, CA125 and CA199 levels in the control group were lower than ineffective group, and the difference was statistically significant (P<0.05). After treatment, the levels of CD3+ T cells, CD4+ T cells, CD4+/CD8+ were negatively correlated with the therapeutic effect (P<0.05), and the levels of CD8+ T cells were positively correlated with the therapeutic effect (P<0.05). Conclusion Immune T lymphocyte subsets are potentially related to the efficacy of chemotherapy combined with targeted therapy in patients with advanced colorectal cancer, which is of great significance for the prognosis of patients.

Key words: advanced colorectal cancer, immune T lymphocyte subsets, immune function, tumor index

中图分类号: 

版权所有 © 2020 《中华养生保健》编辑部     京ICP备20029534号-1